DE69924009D1 - Methode zur verstärkung der biologischen aktivität von liganden - Google Patents

Methode zur verstärkung der biologischen aktivität von liganden

Info

Publication number
DE69924009D1
DE69924009D1 DE69924009T DE69924009T DE69924009D1 DE 69924009 D1 DE69924009 D1 DE 69924009D1 DE 69924009 T DE69924009 T DE 69924009T DE 69924009 T DE69924009 T DE 69924009T DE 69924009 D1 DE69924009 D1 DE 69924009D1
Authority
DE
Germany
Prior art keywords
polypeptide ligands
fusion polypeptide
ligands
increasing
biological activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69924009T
Other languages
English (en)
Other versions
DE69924009T2 (de
Inventor
J Davis
W Gale
D Yancopoulos
Neil Stahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69924009D1 publication Critical patent/DE69924009D1/de
Publication of DE69924009T2 publication Critical patent/DE69924009T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69924009T 1998-12-23 1999-12-23 Methode zur verstärkung der biologischen aktivität von liganden Expired - Lifetime DE69924009T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11338798P 1998-12-23 1998-12-23
US113387P 1998-12-23
PCT/US1999/030900 WO2000037642A1 (en) 1998-12-23 1999-12-23 Method of enhancing the biological activity of ligands

Publications (2)

Publication Number Publication Date
DE69924009D1 true DE69924009D1 (de) 2005-04-07
DE69924009T2 DE69924009T2 (de) 2006-04-13

Family

ID=22349103

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69924009T Expired - Lifetime DE69924009T2 (de) 1998-12-23 1999-12-23 Methode zur verstärkung der biologischen aktivität von liganden

Country Status (12)

Country Link
US (1) US7008781B1 (de)
EP (1) EP1141294B1 (de)
JP (1) JP4493854B2 (de)
AT (1) ATE290089T1 (de)
AU (1) AU776393B2 (de)
CA (1) CA2354846A1 (de)
DE (1) DE69924009T2 (de)
HK (1) HK1040093B (de)
IL (1) IL143558A0 (de)
NZ (1) NZ512326A (de)
PL (1) PL199645B1 (de)
WO (1) WO2000037642A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901428D0 (sv) * 1999-04-21 1999-04-21 Karolinska Innovations Ab Amphibodies
WO2001047951A2 (en) * 1999-12-23 2001-07-05 An-Go-Gen Inc. Angiopoietin analogs
EP1307582B1 (de) * 2000-08-08 2008-05-28 M.G.V.S. Ltd. Nukleinsäurekonstrukte, damit transformierte vaskuläre zellen, pharmezeutische zusammensetzungen und verfahren zur induktion der angiogenese
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US7052695B2 (en) 2001-10-25 2006-05-30 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of treating hypertension
GB0201679D0 (en) * 2002-01-25 2002-03-13 Asterion Ltd Polypeptide variants
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
WO2008100288A2 (en) * 2006-09-15 2008-08-21 The Burnham Institute High affinity ephb receptor binding compounds and methods of use thereof
CA2693383C (en) 2006-10-27 2017-03-28 Sunnybrook Health Sciences Center Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
EP2671891A3 (de) 2008-06-27 2014-03-05 Amgen Inc. Ang-2-Hemmung zur Behandlung von Multipler Sklerose
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2014144600A2 (en) 2013-03-15 2014-09-18 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
PT2983695T (pt) 2013-04-11 2019-09-09 Sunnybrook Res Inst Métodos, usos e composições dos agonistas do tie2
LT3062811T (lt) 2013-11-01 2019-05-10 Regeneron Pharmaceuticals, Inc. Intervencijos angiopoietino pagrindu cerebrinės maliarijos gydymui
EP3370757B1 (de) 2015-11-06 2021-04-14 Regeneron Pharmaceuticals, Inc. Angiopoietine zur förderung der blutgerinnung und zur behandlung von blutgerinnungsstörungen
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090105A1 (en) * 1990-08-29 1992-03-01 Jean-Paul Soulillou Protein polyligands joined to a stable protein core
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2149333C (en) 1992-11-13 2002-01-22 Timothy D. Bartley Eck receptor ligands
US5747033A (en) 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5879672A (en) 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
CA2187167A1 (en) 1994-04-04 1995-10-12 Samuel Davis Biologically active eph family ligands
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5650490A (en) 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
ATE273384T1 (de) 1995-04-06 2004-08-15 Regeneron Pharma Tie-2 liganden, herstellungsverfahren und verwendung
CA2222055A1 (en) * 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
US6602683B1 (en) 1995-10-25 2003-08-05 Regeneron Pharmaceuticals, Inc. Biologically active Eph family ligands
EP0861894B1 (de) * 1995-11-17 2006-03-08 Asahi Kasei Kabushiki Kaisha Polypeptid, das die differenzierung unterdrueckt
US5814478A (en) 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
WO1997023639A1 (fr) 1995-12-22 1997-07-03 Toray Industries, Inc. Procede de production de proteines fusionnees biologiquement actives
EP0939809B1 (de) 1996-06-19 2003-03-26 Regeneron Pharmaceuticals, Inc. Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
US5851797A (en) 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof
US6265564B1 (en) 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule

Also Published As

Publication number Publication date
WO2000037642A1 (en) 2000-06-29
IL143558A0 (en) 2002-04-21
HK1040093B (zh) 2005-05-06
JP4493854B2 (ja) 2010-06-30
WO2000037642A9 (en) 2000-11-02
PL349158A1 (en) 2002-07-01
AU776393B2 (en) 2004-09-09
EP1141294B1 (de) 2005-03-02
ATE290089T1 (de) 2005-03-15
NZ512326A (en) 2003-11-28
JP2003506008A (ja) 2003-02-18
AU2714700A (en) 2000-07-12
PL199645B1 (pl) 2008-10-31
US7008781B1 (en) 2006-03-07
DE69924009T2 (de) 2006-04-13
CA2354846A1 (en) 2000-06-29
HK1040093A1 (en) 2002-05-24
EP1141294A1 (de) 2001-10-10

Similar Documents

Publication Publication Date Title
DE69924009D1 (de) Methode zur verstärkung der biologischen aktivität von liganden
DE3280479D1 (de) Rekombinante DNS-Mittel und Verfahren
ATE212059T1 (de) Methoden zur identifizierung heterofunktionaler fusionsproteine
ATE139784T1 (de) Hybrid-rezeptoren, diese kodierende nukleinsäure, ihre herstellung und ihre verwendung zur bestimmung von liganden sowie deren antagonisten oder agonisten
ATE135371T1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
ATE110108T1 (de) Genetische modifizierung von endothelialen zellen.
HK1025977A1 (en) Oil bodies and associated proteins as affinity matrices
DE50012863D1 (de) Strukturprotein von adeno-assoziiertem virus mit veränderten chromatographischen eigenschaften
DE69941701D1 (de) Mutanten von flt3-l und ihre verwendungen
ATE255420T1 (de) Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
RU2007142191A (ru) Варианты бета-цепи hgf
DE69939330D1 (de) Wachstumsfaktor-homologe zvegf-3
DE69534551D1 (de) Neue methode zum auffindenund bewerten biologisch aktiver moleküle
PT1200561E (pt) Clone celular recombinante estavel, sua producao e utilizacao
ES2192199T3 (es) Ligandos de la familia eph biologicamente activos.
ATE359291T1 (de) Brustkrebsresistenzprotein (bcrp) und für dieses kodierende dna
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
DK1009817T3 (da) RTD-receptor
ATE348171T1 (de) Proteine mit lecithin-cholesterin acetyltransferase-ähnlicher aktivität, deren herstellung und verwendung
DE68917154D1 (de) C-terminus-amidierungsenzym-zusammensetzung, verfahren zur herstellung und verwendung.
EA200000270A1 (ru) КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
ATE334592T1 (de) Biologische bekämpfung von nematoden
DE3782549D1 (de) Neue polypeptide, ihre herstellung und ihre verwendung.
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
EP1331265A3 (de) Durch Zelldichte stimulierte Protein-Tyrosin-Phosphatasen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition